This company has been acquired
Poseida Therapeutics Future Growth
Future criteria checks 2/6
Poseida Therapeutics is forecast to grow earnings and revenue by 21.9% and 29.5% per annum respectively while EPS is expected to grow by 20.8% per annum.
Key information
21.9%
Earnings growth rate
20.8%
EPS growth rate
| Biotechs earnings growth | 27.2% |
| Revenue growth rate | 29.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 10 Dec 2024 |
Recent future growth updates
Recent updates
Poseida Therapeutics: What The Acquisition Offer Says About Big Pharma Priorities
Nov 26Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30%
Oct 19
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
Sep 30Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
Sep 09Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop
Aug 28Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
May 21Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%
Apr 09Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Mar 17Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Jan 24Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)
Aug 13Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding
Apr 17Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech
Sep 04Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M
Aug 11Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B
Aug 03Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
May 15Poseida Therapeutics: Genome Engineering For Safer Cell Therapies
Oct 30Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 102 | -215 | -181 | -174 | 2 |
| 12/31/2026 | 22 | -277 | -165 | -160 | 2 |
| 12/31/2025 | 43 | -220 | -122 | -118 | 3 |
| 12/31/2024 | 147 | -73 | -46 | -44 | 3 |
| 9/30/2024 | 151 | -61 | -17 | -15 | N/A |
| 6/30/2024 | 88 | -113 | 0 | 2 | N/A |
| 3/31/2024 | 83 | -109 | -72 | -69 | N/A |
| 12/31/2023 | 65 | -123 | -95 | -92 | N/A |
| 9/30/2023 | 50 | -131 | -64 | -61 | N/A |
| 6/30/2023 | 157 | -29 | -11 | -7 | N/A |
| 3/31/2023 | 139 | -45 | -17 | -13 | N/A |
| 12/31/2022 | 130 | -64 | -31 | -27 | N/A |
| 9/30/2022 | 152 | -29 | -25 | -21 | N/A |
| 6/30/2022 | 35 | -142 | -126 | -123 | N/A |
| 3/31/2022 | 33 | -145 | -118 | -115 | N/A |
| 12/31/2021 | 31 | -125 | -105 | -103 | N/A |
| 9/30/2021 | N/A | -163 | -146 | -141 | N/A |
| 6/30/2021 | N/A | -155 | -137 | -130 | N/A |
| 3/31/2021 | N/A | -139 | -143 | -129 | N/A |
| 12/31/2020 | N/A | -130 | -130 | -113 | N/A |
| 9/30/2020 | N/A | -117 | -116 | -100 | N/A |
| 6/30/2020 | N/A | -104 | -105 | -89 | N/A |
| 3/31/2020 | N/A | -102 | -81 | -73 | N/A |
| 12/31/2019 | N/A | -87 | -70 | -65 | N/A |
| 9/30/2019 | N/A | -76 | -65 | -60 | N/A |
| 12/31/2018 | N/A | -44 | -39 | -38 | N/A |
| 9/30/2018 | N/A | -36 | -31 | -31 | N/A |
| 12/31/2017 | 3 | -20 | N/A | -23 | N/A |
| 12/31/2016 | 10 | -5 | N/A | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PSTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PSTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PSTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PSTX's revenue (29.5% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: PSTX's revenue (29.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PSTX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 01:31 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Poseida Therapeutics, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| null null | H.C. Wainwright & Co. |
| Yu He | H.C. Wainwright & Co. |